MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2024 International Congress

    Case Report Increasing ‘On-time’ Using Mucuna pruriens Concomitantly with Traditional Levodopa/carbidopa Management

    T. Denne (United States, USA)

    Objective: Case study to see if concomitant use of the botanical Mucuna pruriens with traditional levodopa/carbidopa management could improve patient ‘off-time.’ Background: Mucuna pruriens is a pantropical legume…
  • 2024 International Congress

    Neuronal Exosome based markers in Parkinson’s Disease and Progressive Supranuclear Palsy

    A. Roy, S. Brahmachari, A. Pantelyat, L. Rosenthal, V. Dawson, T. Dawson (Baltimore, USA)

    Objective: This study aimed to explore cellular inflammatory and autophagic mediators in neuronal exosomes of PD and PSP. Background: Parkinson’s disease (PD) is a common…
  • 2024 International Congress

    The Impact of VPS35 D620N Mutation on Alternative Autophagy and its Reversal by Estrogen in Parkinson’s Disease

    T. Shiraishi, K. Bono, Y. Iguchi, H. Okano (Minato-ku, Japan)

    Objective: We investigated the relationship between alternative autophagy and VPS35 D620N mutant-related PD pathogenesis. Background: VPS35 is critically involved in the mechanisms of neurodegeneration observed…
  • 2024 International Congress

    Rora deficiency aggravates dopamine neurons loss via reducing NAD+ level in Parkinson’s disease

    JW. Li, HS. Liu, XY. Hu, T. Wang, N. Xiong (Wuhan, China)

    Objective: To investigate the mechanism by which retinoic acid-related orphan receptor alpha(RORα) regulates NAD+ levels to dopamine neuronal degeneration in Parkinson’s Disease (PD). Background: PD is an age-related degenerative…
  • 2024 International Congress

    Role of RNA splicing in Parkinson’s disease

    K. Irmady, C. Hale, R. Qadri, J. Fak, T. Carroll, R. Darnell (New York, USA)

    Objective: To identify key molecular perturbations affecting medium spiny neuron functions and their role in the clinical symptoms of Parkinson’s disease (PD). Background: The degeneration…
  • 2024 International Congress

    Preclinical Studies: Investigating Serum-Based Exosomal miRNAs in Prodromal Drug-Induced Parkinson’s Disease

    M. Ahmad (Hyderabad, India)

    Objective: This work aims to elucidate the identification of homologs of miRNAs in a pronormal stage of Parkinson`s disease. Background: Parkinson's disease (PD) is defined…
  • 2024 International Congress

    ECAP-Controlled Closed-Loop SCS Alleviates Neuropathic Pain and Improves Motor Function in a Patient Suffering from Parkinson’s Disease and Radicular Pain

    Z. Zamfirov, D. Mugan, G. Ahluwalia (Annapolis, USA)

    Objective: The objective of this case report is to highlight the effect of a new technology, Evoked Compound Action Potential (ECAP) controlled closed-loop spinal cord…
  • 2024 International Congress

    Levodopa-Entacapone-Carbidopa Intestinal Gel Treatment In Parkinson’s Disease: A Single-Center Retrospective Chart Study

    AA. Vanderplas (Leiderdorp, Netherlands)

    Objective: The objectives of this chart study were to evaluate adaptations in medication and flow rates and adverse events in patients with Parkinson’s disease (PD)…
  • 2024 International Congress

    AAV-mediated gene therapy for GBA-PD

    S. Ayloo, J. Ryu, S. Chou, C. Miller, L. Blatnik, E. Wischhof, J. Bu, W. Mccarty, L. Guo, S. Nass, C. O'Riordan, B. Elmer, C. Mueller, S. Ramachandran (Waltham, USA)

    Objective: Development of a gene therapy-based drug for treatment of GBA-PD, a genetic subtype of Parkinson’s disease Background: Mutations in GBA1, the gene encoding glucocerebrosidase…
  • 2024 International Congress

    The effects of DL-3-n-butylphthalide in patients with mild cognitive impairment due to Parkinson’s disease: A multicenter, randomized, double-blind, placebo-controlled trial

    C. Han, Y. Xia, J. Wu, Y. Sun, L. Kou, J. Huang, Q. Wang, E. Xu, H. Yu, Q. Ye, X. Luo, H. Ma, H. Chen, L. Wang, T. Wang (wuhan, China)

    Objective: To assess the therapeutic effect of DL-3-n-butylphthalide on cognitive impairment associated with Parkinson’s disease (PD). Background: PD associated cognitive impairment are attracting attention because…
  • « Previous Page
  • 1
  • …
  • 419
  • 420
  • 421
  • 422
  • 423
  • …
  • 1942
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley